SCHEMBL4715873

SCHEMBL4715873

Cc1ccc(Cn2ccc3c2ccc(=O)n3-c2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 3/20 0.44
NPC1 O15118 1/20 0.44
BRD4 O60885 1/20 0.44
THRB P10828 1/20 0.42
LMNA P02545 3/20 0.40
P2RX4 Q99571 1/20 0.40
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713845 0.90 BRD4 (0.46) TP53MEN1KMT2AHTTNPC1
SCHEMBL4714110 0.88 LMNA (0.44) TP53MAPTPOLBMEN1KMT2A
SCHEMBL5124227 0.86 SMN1; SMN2 (0.43) TP53MAPTHTTBRD4THRB
SCHEMBL4713858 0.86 MAPT (0.46) TP53MAPTPOLBMEN1KMT2A
SCHEMBL5113137 0.84 HTR6 (0.44) HTTBRD4LMNAKDM4ESMN1; SMN2
SCHEMBL4716129 0.83 CYP11B1 (0.41) POLBKMT2AHTTLMNAKDM4E
SCHEMBL4715863 0.83 CYP3A4 (0.46) TP53MAPTPOLBMEN1KMT2A
SCHEMBL4713444 0.81 POLB (0.44) TP53MAPTPOLBMEN1KMT2A
SCHEMBL4714450 0.81 RGS4 (0.46) TP53MAPTBRD4LMNAKDM4E
SCHEMBL4761608 0.81 MAPT (0.36) TP53MAPTPOLBHTTBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 TP53 740/4885MAPT 1831/4885POLB 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.